ArticleEuropean journal of case reports in internal medicine2026
Invariant Natural Killer T Cell-Based Immunotherapy Using α-Galactosylceramide-Pulsed CD14
Article in European journal of case reports in internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gallbladder cancer is a rare and aggressive malignancy. Patients with unresectable or metastatic disease generally have poor outcomes despite standard chemotherapy. Novel immunotherapeutic strategies that enhance antitumor immunity are of considerable clinical interest. Invariant natural killer T (iNKT) cells rapidly produce cytokines and activate immune effector cells, representing a potential target for immunotherapy. Case description: We report a case of advanced gallbladder cancer treated with gemcitabine chemotherapy in combination with autologous iNKT cell-targeted therapy. Peripheral blood CD14 Discussion: Although the specific contribution of immunotherapy cannot be definitively separated from concomitant chemotherapy, the temporal association between α-GalCer-pulsed CD14 Conclusion: iNKT cell-targeted immunotherapy using GC-MO may serve as a promising adjunctive strategy for advanced gallbladder cancer. Further studies are warranted to validate its efficacy and define its role in combination with conventional chemotherapy. LEARNING POINTS: Invariant natural killer T (iNKT) cells play an important role in antitumor immunity by rapidly producing cytokines and activating multiple immune effector cells, including NK cells and cytotoxic T lymphocytes.α-Galactosylceramide-pulsed CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.